Deferasirox是什么药品？

(Deferasirox, Enriga) may cause rash. Generally, the rash will disappear automatically without the need to adjust the dose or stop the medication; if the situation is serious or persistent, the medication should be stopped. The patient's vision or hearing may be affected. It should be taken 30 minutes before meals. It should be taken at the same time every day. Deferasirox (Deferasirox, Enrig) ​​should not be taken with aluminum-containing drugs (such as gastric acid neutralizers). So, what kind of drug is Deferasirox?

The chemical name of Deferasirox (Deferasirox, Enrig) is 4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid. It is an iron chelator product developed by the Swiss pharmaceutical company Novartis. It is the first oral iron dispelling agent approved by the US FDA for routine use. It is approved for use in patients ≥2 years old with chronic iron overload caused by blood transfusion. In Europe, it is recommended as a 6 First-line drug for patients with thalassemia and iron overload over 10 years of age.

Deferasirox dispersible tablets should be taken once daily on an empty stomach, at least 30 minutes before a meal, preferably at the same time each day. Tablets should not be chewed or swallowed whole. Deferasirox (Deferasirox, Enrig) ​​dispersible tablets should not be taken together with aluminum-containing antacids, and the dose (mg/kg) needs to be calculated and rounded to the nearest whole tablet. Completely dissolve the tablets in water, apple juice or orange juice (100-200mL) by stirring until a clear suspension is obtained and then drink it. The remaining medicine must be added with a small amount of water, apple juice or orange juice and mixed well before being taken. Not recommended for dissolution in carbonated drinks or milk as it can cause foaming and slow dispersion.

Common adverse reactions of Deferasirox (Deferasirox, Enrig) include: diarrhea, vomiting, headache, abdominal pain, fever, rash, increased serum creatinine (Creatinine), etc. Other adverse reactions include: increased liver enzymes, cough, throat inflammation, and urticaria. In addition, Deferasirox (Deferasirox, Enrige) dispersible tablets should not be taken together with drugs containing aluminum (such as gastric acid neutralizers).

While taking Deferasirox (Deferasirox, Enrig), patients with thalassemia are often physically weak, so they should live cautiously, adapt to cold temperatures, and pay attention to preventing external infections; engage in more outdoor activities; breathe fresh air; and perform appropriate physical exercises, Qigong exercises, Tai Chi, etc. to enhance physical fitness and disease resistance.

The above is the content of the drug introduction of (Deferasirox, Enriga), I hope it can help you!